Page 66 - Haematologica August 2018

1302
C. Gambacorti-Passerini et al.
or more after transformation: one patient who trans- formed on day 14 continued bosutinib treatment for another six years and subsequently continued treatment in the extension study; another patient who transformed on day 246 discontinued treatment two years later for PD. Among 153 patients remaining on treatment after year 2, only 2 (both IM-R) had on-treatment transformation to AP
A
after this time (on days 734 and 2165). Eleven of the 15 patients with on-treatment transformation had responses to bosutinib, including 4 with best responses of MCyR, 3 with CCyR, and 4 with CHR. The cumulative incidence of on-treatment PD/death was higher by 4% at year 5 [19% (IM-R, 23%; IM-I, 10%)] versus year 2 [15% (IM-R, 19%; IM-I, 7%)]; 42% of patients discontinued treatment
B
Figure 1. Duration of response.
Duration of major cytogenetic response (MCyR) (A) and com- plete cytogenetic response (CCyR) (B) among responders. Open circles indicate censored observations. IM-I: imatinib- intolerant; IM-R: imatinib-resis- tant; n: number; d: day.
haematologica | 2018; 103(8)